BUZZ-Salarius 在完成与 Decoy Therapeutics 的合并后大幅上涨

路透中文

11/13

BUZZ-Salarius 在完成与 Decoy <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 的合并后大幅上涨

11月13日 - ** 药物开发商 Salarius Pharmaceuticals SLRX.O早盘股价上涨 17.3% 至 1.22 美元

** 公司与 Decoy Therapeutics 完成合并，整合资源加速开发治疗严重疾病的多肽药物 - SLRX

** 合并后的公司更名为 Decoy Therapeutics，专注于推进 Decoy 的产品线，包括呼吸道感染和胃肠道癌症的治疗。

** SLRX 称，Decoy 的联合创始人 Frederick "Rick" Pierce 担任首席执行官

** Decoy 的技术利用人工智能和快速制造技术快速设计和生产候选药物 - SLRX

** Decoy 获得机构投资者和马萨诸塞州生命科学公司、谷歌、英伟达公司和强生公司项目的资金支持

** 包括本交易日的走势在内，该股今年累计下跌约 94

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/news/2583599598"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583599598\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583599598?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-13 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583599598","market":"us","top_or_hot":-1,"title":"BUZZ-Salarius 在完成与 Decoy Therapeutics 的合并后大幅上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Salarius 在完成与 Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 的合并后大幅上涨</title></head><body><p><span>11月13日</span><span> - </span>** 药物开发商 Salarius Pharmaceuticals <span>SLRX.O</span>早盘股价上涨 17.3% 至 1.22 美元 </p><p>** 公司与 Decoy Therapeutics 完成合并，整合资源加速开发治疗严重疾病的多肽药物 - SLRX</p><p>** 合并后的公司更名为 Decoy Therapeutics，专注于推进 Decoy 的产品线，包括呼吸道感染和胃肠道癌症的治疗。</p><p>** SLRX 称，Decoy 的联合创始人 Frederick \"Rick\" Pierce 担任首席执行官</p><p>** Decoy 的技术利用人工智能和快速制造技术快速设计和生产候选药物 - SLRX</p><p>** Decoy 获得机构投资者和马萨诸塞州生命科学公司、<a href=\"https://laohu8.com/S/GOOG\">谷歌</a>、<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>公司和<a href=\"https://laohu8.com/S/JNJ\">强生</a>公司项目的资金支持</p><p>** 包括本交易日的走势在内，该股今年累计下跌约 94</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Salarius 在完成与 Decoy Therapeutics 的合并后大幅上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Salarius 在完成与 Decoy Therapeutics 的合并后大幅上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-11-13 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Salarius 在完成与 Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 的合并后大幅上涨</title></head><body><p><span>11月13日</span><span> - </span>** 药物开发商 Salarius Pharmaceuticals <span>SLRX.O</span>早盘股价上涨 17.3% 至 1.22 美元 </p><p>** 公司与 Decoy Therapeutics 完成合并，整合资源加速开发治疗严重疾病的多肽药物 - SLRX</p><p>** 合并后的公司更名为 Decoy Therapeutics，专注于推进 Decoy 的产品线，包括呼吸道感染和胃肠道癌症的治疗。</p><p>** SLRX 称，Decoy 的联合创始人 Frederick \"Rick\" Pierce 担任首席执行官</p><p>** Decoy 的技术利用人工智能和快速制造技术快速设计和生产候选药物 - SLRX</p><p>** Decoy 获得机构投资者和马萨诸塞州生命科学公司、<a href=\"https://laohu8.com/S/GOOG\">谷歌</a>、<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>公司和<a href=\"https://laohu8.com/S/JNJ\">强生</a>公司项目的资金支持</p><p>** 包括本交易日的走势在内，该股今年累计下跌约 94</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVIW.SI","symbol_name":"NVDA 3xLongSG261006","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4S3WP14L:1","article_id":"2583599598","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583599598","pubTimestamp":1763044686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Salarius 在完成与 Decoy Therapeutics 的合并后大幅上涨11月13日 - ** 药物开发商 Salarius Pharmaceuticals SLRX.O早盘股价上涨 17.3% 至 1.22 美元 ** 公司与 Decoy Therapeutics 完成合并，整合资源加速开发治疗严重疾病的多肽药物 - SLRX** 合并后的公司更名为 Decoy Therapeutics，专注于推进 Decoy 的产品线，包括呼吸道感染和胃肠道癌症的治疗。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVIW.SI":"NVDA 3xLongSG261006","3NVD.UK":"LS 3X NVIDIA","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1935043536.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC A","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","NVDS":"Tradr 1.5X Short NVDA Daily ETF","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0215105999.USD":"SCHRODER ISF GLOBAL EQUITY \"A\" ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0345768153.USD":"NINETY ONE GSF GLOBAL STRATEGIC MANAGED \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","NVDU":"Direxion Daily NVDA Bull 2X Shares","LU0557290698.USD":"施罗德环球可持续增长基金","BK4549":"软银资本持仓","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4077":"互动媒体与服务","SNVD.UK":"LS -1X NVIDIA","BK4548":"巴美列捷福持仓","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","NVD2.UK":"2X NVIDIA ETP","JNJ":"强生","NVDX":"T-REX 2X LONG NVIDIA DAILY TARGET ETF","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","NVD":"GraniteShares 2x Short NVDA Daily ETF","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","NVDY":"YIELDMAX NVDA OPTION INCOME STRATEGY ETF","NVD3.UK":"LS 3X NVIDIA","2NVD.UK":"2X NVIDIA ETP","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","NVDS.UK":"LS -1X NVIDIA","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SLRX":"Salarius Pharmaceuticals Inc","NVDD":"Direxion Daily NVDA Bear 1X Shares","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","LU0056508442.USD":"贝莱德世界科技基金A2","BK4554":"元宇宙及AR概念","LU0823414478.USD":"法巴经典能源转换基金","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC"},"translate_title":"BUZZ-Salarius Jumps After Completing Merger with Decoy Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"2NVD.UK":0.6,"3NVD.UK":0.6,"JNJ":0.9,"NVD":0.6,"NVD2.UK":0.6,"NVD3.UK":0.6,"NVDD":0.6,"NVDS":0.6,"NVDS.UK":0.6,"NVDU":0.6,"NVDX":0.6,"NVDY":0.6,"NVIW.SI":0.6,"SLRX":0.9,"SNVD.UK":0.6},"content_text":"BUZZ-Salarius 在完成与 Decoy Therapeutics 的合并后大幅上涨11月13日 - ** 药物开发商 Salarius Pharmaceuticals SLRX.O早盘股价上涨 17.3% 至 1.22 美元 ** 公司与 Decoy Therapeutics 完成合并，整合资源加速开发治疗严重疾病的多肽药物 - SLRX** 合并后的公司更名为 Decoy Therapeutics，专注于推进 Decoy 的产品线，包括呼吸道感染和胃肠道癌症的治疗。** SLRX 称，Decoy 的联合创始人 Frederick \"Rick\" Pierce 担任首席执行官** Decoy 的技术利用人工智能和快速制造技术快速设计和生产候选药物 - SLRX** Decoy 获得机构投资者和马萨诸塞州生命科学公司、谷歌、英伟达公司和强生公司项目的资金支持** 包括本交易日的走势在内，该股今年累计下跌约 94(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}